Collagen peptides are the most searched skincare ingredient on Google — and for understandable reasons. The premise is intuitive: skin loses collagen with age, so consuming collagen should restore it. The global collagen peptide market reflects that logic. Billions of dollars of products are sold annually on the back of it.
The problem is the mechanism. When you ingest collagen peptides — whether in a supplement or a drink — your digestive system breaks them into individual amino acids before they can reach the skin. The body then uses those amino acids as it sees fit. There is no direct delivery of collagen to the dermis. The skin receives the same amino acid pool it would receive from any protein-rich meal.
This is not a criticism of nutrition. Adequate protein intake supports skin health. But it is not the same as targeted collagen synthesis — and the distinction matters when evaluating what a product is actually doing.
Bioregulator peptides operate through a different mechanism entirely. Rather than supplying building blocks and hoping the body allocates them to skin tissue, bioregulator compounds carry a biological signal directly to the cell. Short-chain peptides — two to seven amino acids — cross cell membranes, enter the nucleus, and bind to DNA promoter sequences. They activate gene expression that controls collagen synthesis at the cellular level, in the specific tissue they are designed for.
GHK-Cu is the example most relevant to skin. Published research spanning five decades documents GHK-Cu's activation of fibroblast collagen synthesis — the actual cellular mechanism that produces new collagen in the dermis. Not by supplying amino acids. By signaling the cell to produce collagen through its own biological pathway.
The distinction is the difference between supplying ingredients and activating the process. Both have a role. But they are not the same thing, and the consumer who understands the difference is in a significantly better position to evaluate what they are purchasing.
The HelioMend Khavinson Collection is built on bioregulator compounds — not collagen peptides. The Structure Protocol delivers GHK-Cu in a freeze-dried format that preserves compound integrity through to point of use. The research behind it spans six decades of published Khavinson bioregulator science.